GERN GERON CORP Insider Trading

Director V Bryan bought 13,300 (13.3K shares) of GERN at $1.18; stock down -76.4% from 52-week high, company unprofitable with -60.2% annual revenue decline.

Director V Bryan purchased 13,300 shares of Geron at $1.18 on 2025-05-09, initiating a position of 13,300 shares. The purchase occurs amid significant deterioration in the company's fundamentals: annual revenue growth contracted -60.2%, the company generated net income of $-19.8M despite quarterly revenue of $39.6M, and the stock trades at $1.20 today, down -76.4% from its 52-week high of $5.09 and down -57.0% over the 90-day period. This buy represents an insider director's first acquisition at what appears to be near multi-month lows, though the broader context of severe revenue collapse and operating losses suggests the stock reflects substantial business deterioration rather than isolated market dislocations.

GERN CEO John A. Scarlett buys 12,500 shares at $1.76 as stock down -66.4% from 52-week high; 2 other insiders bought within 14 days.

CEO Scarlett John A purchased 12,500 shares (12.5K shares) at $1.76 on 2025-02-27, establishing an initial stake in GERON after holding zero shares previously. The purchase occurs amid significant share price deterioration: the stock is -66.4% from its 52-week high of $5.09 and down -40.4% over the past 30 days and -56.7% over 90 days. Notably, a cluster pattern is present—2 other insiders also bought within the past 14 days—suggesting coordinated or coincident insider confidence during a period of sharp decline. However, the company's fundamentals present a counterweight: annual revenue declined -60.2% year-over-year to $28,271,000.00 ($28.3M) in the latest quarter, with a net loss of $-26,447,000.00 ($-26.4M), indicating the firm has been unprofitable over its most recent full fiscal year. The convergence of depressed valuation, clustered insider buying, and deteriorating business performance creates a complex signal warranting closer examination of the underlying drivers.

GERON's Chief Legal Officer purchased 15,000 shares at $1.61 on 2025-02-27, doubling holdings to 26.7K; stock down -66.4% from 52-week high and company unprofitable with -60.2% annual revenue decline.

Scott Alan Samuels, EVP and Chief Legal Officer, purchased 15,000 shares at $1.61, increasing his holdings from 11.7K to 26.7K shares—a net increase of +128.4% relative to pre-transaction holdings. The purchase occurs in a deteriorated context: GERON's stock has fallen -40.4% over the past 30 days and -56.7% over 90 days, trading 66.4% below its 52-week high of $5.09. Fundamentally, the company reported a net loss of $-26.4M on quarterly revenue of $28.3M, and annual revenue has contracted by -60.2% year-over-year, with the company unprofitable over its most recent full fiscal year. A cluster pattern is present—two other insiders also purchased shares within the past 14 days—which may indicate coordinated conviction at depressed valuation levels. The concentration of executive buying amid sustained losses and severe revenue decline warrants examination of what conviction (if any) management perceives about the business trajectory.

EVP James Ziegler buys 100,000 shares at $1.60; 2 other insiders also bought in past 14 days amid -66.4% decline from 52-week high

James Ziegler, the Chief Commercial Officer, initiated a position by purchasing 100,000 shares at $1.60 on 2025-02-27, with the stock now trading at $1.71 after declining 66.4% from its 52-week high of $5.09 and 40.4% over the past 30 days. The purchase occurs within a cluster pattern in which 2 other insiders also bought within the past 14 days, suggesting coordinated or parallel interest at depressed price levels. The company's fundamentals remain challenged, with negative net income of $26.4M against quarterly revenue of $28.3M and annual revenue decline of 60.2%, underscoring that this transaction occurs against deteriorating operational performance rather than positive business momentum. The timing and multi-insider participation warrant attention to what signals management is reading about the stock's recovery trajectory and whether this reflects conviction about a valuation bottom.

COO Andrew Grethlein sells entire 674.3K share stake at $4.56, eliminating all GERN holdings

Andrew Grethlein, EVP and Chief Operating Officer, liquidated his entire 674,348-share position in a single transaction at $4.56 on 2024-07-08, leaving him with 0 shares post-transaction. This complete exit by a C-suite operator at a biotech company trading with a market cap of $2,728,409,684.00 comes amid significant headwinds: the company recorded revenue of $304,000.00 in its latest quarter and net income of $-55,390,000.00, with annual revenue declining 60.2% year-over-year. The full elimination of holdings by a chief operating officer—the executive responsible for day-to-day operations—signals a decisive capital event, particularly in a context where the company is unprofitable and facing sharp revenue contraction. While stock price context shows the sale occurred 9.6% below the 52-week high of $5.09, the material fact is the complete departure from ownership by an executive in direct operational position during a period of financial stress.